HRP20241052T1 - Semaglutid, namijenjen liječenju alzheimerove demencije - Google Patents
Semaglutid, namijenjen liječenju alzheimerove demencije Download PDFInfo
- Publication number
- HRP20241052T1 HRP20241052T1 HRP20241052TT HRP20241052T HRP20241052T1 HR P20241052 T1 HRP20241052 T1 HR P20241052T1 HR P20241052T T HRP20241052T T HR P20241052TT HR P20241052 T HRP20241052 T HR P20241052T HR P20241052 T1 HRP20241052 T1 HR P20241052T1
- Authority
- HR
- Croatia
- Prior art keywords
- glp
- receptor agonist
- semaglutide
- intended
- accordance
- Prior art date
Links
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 title claims 19
- 229950011186 semaglutide Drugs 0.000 title claims 19
- 108010060325 semaglutide Proteins 0.000 title claims 19
- 208000024827 Alzheimer disease Diseases 0.000 title claims 4
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 28
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims 28
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 1
- 208000015756 familial Alzheimer disease Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical class CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- UOENJXXSKABLJL-UHFFFAOYSA-M sodium;8-[(2-hydroxybenzoyl)amino]octanoate Chemical compound [Na+].OC1=CC=CC=C1C(=O)NCCCCCCCC([O-])=O UOENJXXSKABLJL-UHFFFAOYSA-M 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19207501 | 2019-11-06 | ||
| EP20186623 | 2020-07-20 | ||
| PCT/EP2020/081087 WO2021089678A1 (en) | 2019-11-06 | 2020-11-05 | Glp-1 receptor agonists in dementia |
| EP20803489.2A EP4054620B1 (en) | 2019-11-06 | 2020-11-05 | Semaglutide in the treatment of alzheimer's dementia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241052T1 true HRP20241052T1 (hr) | 2024-11-08 |
Family
ID=73172681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241052TT HRP20241052T1 (hr) | 2019-11-06 | 2020-11-05 | Semaglutid, namijenjen liječenju alzheimerove demencije |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20220280612A1 (https=) |
| EP (2) | EP4414031A3 (https=) |
| JP (2) | JP7670698B2 (https=) |
| KR (1) | KR20220110731A (https=) |
| CN (1) | CN114728042A (https=) |
| AU (1) | AU2020377469A1 (https=) |
| BR (1) | BR112022007721A2 (https=) |
| CA (1) | CA3154744A1 (https=) |
| ES (1) | ES2984177T3 (https=) |
| HR (1) | HRP20241052T1 (https=) |
| HU (1) | HUE067514T2 (https=) |
| IL (1) | IL291876A (https=) |
| MA (1) | MA57599B1 (https=) |
| MX (1) | MX2022004779A (https=) |
| PH (1) | PH12022550842A1 (https=) |
| PL (1) | PL4054620T3 (https=) |
| RS (1) | RS65780B1 (https=) |
| TW (1) | TWI890704B (https=) |
| WO (1) | WO2021089678A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL291876A (en) | 2019-11-06 | 2022-06-01 | Novo Nordisk As | Receptor agonists in glp-1 type dementia |
| KR20220132606A (ko) * | 2020-01-30 | 2022-09-30 | 일라이 릴리 앤드 캄파니 | 둘라글루티드의 치료 용도 |
| US20240050531A1 (en) * | 2020-12-16 | 2024-02-15 | The Chinese University Of Hong Kong | A method for reversing aging brain functional decline |
| KR20240123816A (ko) | 2021-12-02 | 2024-08-14 | 쾨벤하운스 유니버시테트 | 퇴행성 신경 질환의 치료를 위한 펩티드-약물 접합체 |
| WO2024179606A1 (zh) * | 2023-03-02 | 2024-09-06 | 甘李药业股份有限公司 | 一种glp-1化合物的医药用途 |
| CN120131965A (zh) * | 2025-04-10 | 2025-06-13 | 瓯江实验室 | Glp-1受体激动剂治疗阿尔茨海默病的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650386A (en) | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| AU3357800A (en) | 1999-02-05 | 2000-08-25 | Emisphere Technologies, Inc. | Method of preparing alkylated salicylamides |
| WO2001092206A1 (en) | 2000-06-02 | 2001-12-06 | Emisphere Technologies, Inc. | Method of preparing salicylamides |
| ATE408414T1 (de) | 2001-07-31 | 2008-10-15 | Us Gov Health & Human Serv | Glp 1 exendin 4 peptidanaloga und deren verwendungen |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN101258163B (zh) | 2005-06-30 | 2013-08-21 | 益普生制药股份有限公司 | Glp-1药物组合物 |
| WO2007121318A2 (en) | 2006-04-12 | 2007-10-25 | Emisphere Technologies, Inc. | Formulations for delivering insulin |
| US8501693B2 (en) | 2006-08-04 | 2013-08-06 | Amylin Pharmaceuticals, Llc | Use of exendins and exendin agonists and GLP-1 receptor agonists for altering the concentration of fibrinogen |
| BRPI0716539A2 (pt) | 2006-09-07 | 2016-11-01 | Emisphere Tech Inc | métodos para sintetização de ácido n-(8-[2-hidroxibenzoil]amino) caprílico e de sal de sódio deste |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| SI2651398T1 (en) * | 2010-12-16 | 2018-04-30 | Novo Nordisk A/S | SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND SOL N- (8- (2-HYDROXYBENZOIL) AMINO) CAPRICULATE ACIDS |
| PL2696687T3 (pl) | 2011-04-12 | 2017-06-30 | Novo Nordisk A/S | Pochodne podwójnie acylowanej GLP-1 |
| WO2013004983A1 (en) | 2011-07-04 | 2013-01-10 | Imperial Innovations Limited | Novel compounds and their effects on feeding behaviour |
| EP2866825B1 (en) * | 2012-07-01 | 2020-04-08 | Novo Nordisk A/S | Use of long-acting glp-1 peptides |
| ES2741507T3 (es) | 2014-04-07 | 2020-02-11 | Novo Nordisk As | Compuestos de glp-1 acilados doblemente |
| WO2016198624A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| US20170112897A1 (en) * | 2015-10-23 | 2017-04-27 | Cedars-Sinai Medical Center | Methods for treating brain insulin resistance |
| CN108697768B (zh) | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | 长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法 |
| US20190142905A1 (en) | 2016-04-19 | 2019-05-16 | Ureka Sarl | Peptide-oligourea foldamer compounds and methods of their use |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| IL291876A (en) | 2019-11-06 | 2022-06-01 | Novo Nordisk As | Receptor agonists in glp-1 type dementia |
| JP7761567B2 (ja) | 2020-02-18 | 2025-10-28 | ノヴォ ノルディスク アー／エス | 医薬製剤 |
-
2020
- 2020-11-05 IL IL291876A patent/IL291876A/en unknown
- 2020-11-05 PH PH1/2022/550842A patent/PH12022550842A1/en unknown
- 2020-11-05 KR KR1020227015440A patent/KR20220110731A/ko active Pending
- 2020-11-05 EP EP24175772.3A patent/EP4414031A3/en active Pending
- 2020-11-05 JP JP2022521146A patent/JP7670698B2/ja active Active
- 2020-11-05 CA CA3154744A patent/CA3154744A1/en active Pending
- 2020-11-05 HU HUE20803489A patent/HUE067514T2/hu unknown
- 2020-11-05 CN CN202080076976.0A patent/CN114728042A/zh active Pending
- 2020-11-05 MA MA57599A patent/MA57599B1/fr unknown
- 2020-11-05 MX MX2022004779A patent/MX2022004779A/es unknown
- 2020-11-05 AU AU2020377469A patent/AU2020377469A1/en active Pending
- 2020-11-05 BR BR112022007721A patent/BR112022007721A2/pt unknown
- 2020-11-05 HR HRP20241052TT patent/HRP20241052T1/hr unknown
- 2020-11-05 RS RS20240863A patent/RS65780B1/sr unknown
- 2020-11-05 PL PL20803489.2T patent/PL4054620T3/pl unknown
- 2020-11-05 WO PCT/EP2020/081087 patent/WO2021089678A1/en not_active Ceased
- 2020-11-05 ES ES20803489T patent/ES2984177T3/es active Active
- 2020-11-05 EP EP20803489.2A patent/EP4054620B1/en active Active
- 2020-11-06 TW TW109138851A patent/TWI890704B/zh active
-
2022
- 2022-05-04 US US17/736,116 patent/US20220280612A1/en not_active Abandoned
-
2023
- 2023-06-12 US US18/208,485 patent/US20230302094A1/en not_active Abandoned
-
2024
- 2024-01-30 US US18/426,412 patent/US20240207364A1/en active Pending
- 2024-12-04 JP JP2024211204A patent/JP2025027130A/ja active Pending
- 2024-12-12 US US18/979,068 patent/US12539326B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230302094A1 (en) | 2023-09-28 |
| EP4054620A1 (en) | 2022-09-14 |
| EP4414031A3 (en) | 2025-02-05 |
| EP4054620C0 (en) | 2024-05-29 |
| CA3154744A1 (en) | 2021-05-14 |
| HUE067514T2 (hu) | 2024-10-28 |
| EP4414031A2 (en) | 2024-08-14 |
| JP2023500032A (ja) | 2023-01-04 |
| RS65780B1 (sr) | 2024-08-30 |
| WO2021089678A1 (en) | 2021-05-14 |
| MA57599B1 (fr) | 2024-06-28 |
| CN114728042A (zh) | 2022-07-08 |
| TW202519256A (zh) | 2025-05-16 |
| US12539326B2 (en) | 2026-02-03 |
| KR20220110731A (ko) | 2022-08-09 |
| ES2984177T3 (es) | 2024-10-29 |
| US20220280612A1 (en) | 2022-09-08 |
| TW202118509A (zh) | 2021-05-16 |
| AU2020377469A1 (en) | 2022-04-28 |
| MX2022004779A (es) | 2022-06-14 |
| JP7670698B2 (ja) | 2025-04-30 |
| EP4054620B1 (en) | 2024-05-29 |
| JP2025027130A (ja) | 2025-02-26 |
| IL291876A (en) | 2022-06-01 |
| TWI890704B (zh) | 2025-07-21 |
| US20250099549A1 (en) | 2025-03-27 |
| US20240207364A1 (en) | 2024-06-27 |
| PL4054620T3 (pl) | 2024-10-14 |
| PH12022550842A1 (en) | 2023-10-09 |
| BR112022007721A2 (pt) | 2022-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241052T1 (hr) | Semaglutid, namijenjen liječenju alzheimerove demencije | |
| JP2023500032A5 (https=) | ||
| HRP20251112T1 (hr) | Čvrsti pripravci koji sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| RU2729066C2 (ru) | Диацереин или его аналоги для ингибирования экспрессии asc, экспрессии nlrp3 и/или образования комплекса nlrp3 инфламмасом | |
| HRP20251261T1 (hr) | Inhibitori csf1r za uporabu u liječenju tenosinovijalnih gigantocelularnih tumora | |
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
| CN105209036B (zh) | 氧杂双环庚烷和氧杂双环庚烯的配制品 | |
| JP2009514874A5 (https=) | ||
| ATE332138T1 (de) | Flibanserin zur behandlung extrapyramidaler bewegungsstörungen | |
| BR112017026417B1 (pt) | Formulação para o tratamento de distúrbios da boca, garganta e vias respiratórias | |
| IL265761B1 (en) | Oral terlipressin compositions for use in treatment of ascites | |
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| BRPI0914086A2 (pt) | uso de paracetamol e ibuprofeno na preparação de um medicamento para o tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa e método de tratamento de osteoartrite moderada ou severa ou artrite reumatoide moderada ou severa | |
| Hagino et al. | Tocilizumab for systemic juvenile idiopathic arthritis | |
| HRP20211661T1 (hr) | Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti | |
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| HRP20211492T1 (hr) | Liraglutid, namijenjen upotrebi kod kardiovaskularnih stanja | |
| JP2019535830A5 (https=) | ||
| US11458160B2 (en) | Food supplements for use in the prophylaxis and treatment of migraine | |
| ES2424417B1 (es) | Combinación de un aine y un aminoacido | |
| BR112020017773A2 (pt) | Composição farmacêutica compreendendo polmacoxibe e pregabalina para tratamento de dor | |
| HRP20230677T1 (hr) | Kombinacija ibuprofena i tramadola za ublažavanje boli | |
| KR20210021356A (ko) | 항-n-메틸-d-아스파르테이트 수용체(anti-n-methyl-d-aspartate receptor) 뇌염 예방 또는 치료에 사용하기 위한 벤조산 또는 이의 염 및 유도체 | |
| TH2201000080A (th) | การรวมกันของไอบูโพรเฟนและทรามาดอลสำหรับการบรรเทาอาการปวด |